Champions Oncology Launches Comprehensive Radiopharmaceutical Services Platform with Expanded Isotope Capabilities
核心洞察
Champions Oncology has launched a fully integrated radiopharmaceutical services platform combining advanced radiochemistry infrastructure with their extensive patient-derived xenograft tumor model bank.
The company expanded its radioactive materials license to support ten key isotopes including Lu-177, Ac-225, and Y-90, enabling radioligand therapy, antibody radionuclide conjugates, and theranostic approaches.
More than thirty PDX models have been successfully screened in collaboration with pharmaceutical and biotech partners, providing clinically relevant systems for evaluating radiolabeled agents.
Champions Oncology (NASDAQ:CSBR), a leading translational oncology research organization, announced the full commercial launch of its radiopharmaceutical services platform, marking a significant expansion into one of precision oncology's most promising therapeutic areas. The milestone follows the company's expansion of its radioactive materials license, completion of radiochemistry infrastructure, and successful screening of more than thirty patient-derived xenograft (PDX) models in collaboration with pharmaceutical and biotech partners.
Integrated Platform Combines Advanced Infrastructure with Clinical Relevance
The newly launched platform offers fully integrated radiopharmaceutical workflows that combine in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. Champions' platform distinguishes itself through its extensive bank of patient-derived xenograft tumor models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems.
"Radiopharmaceuticals represent one of the most exciting frontiers in precision oncology," said Mike Ritchie, Chief Commercial Officer at Champions Oncology. "By combining advanced radiochemistry infrastructure with the world's most deeply characterized PDX bank, we're helping our clients generate meaningful, translational data that drives confident decision-making earlier in oncology drug development."
Expanded Isotope Capabilities Enable Diverse Therapeutic Approaches
Champions' updated radioactive materials license now includes support for ten key isotopes: Lu-177, Ac-225, In-111 (搜索), Cu-67 (搜索), Y-90, Pb-212, At-211, Tb-161 (搜索), Cu-64 (搜索), and Zr-89 (搜索). These additions enable a wide range of study designs including radioligand therapy (RLT), antibody radionuclide conjugates (ARCs), and theranostic approaches.
The expanded isotope portfolio positions Champions to support the growing radiopharmaceutical sector, which has gained significant momentum following recent regulatory approvals and clinical successes in targeted cancer therapy.
Preclinical Platform Addresses Critical Development Needs
"Our goal is to help biopharma partners answer critical questions faster, with data that reflects real tumor biology," continued Ritchie. "The integration of radionuclide workflows into our PDX platform provides a uniquely powerful preclinical toolset for evaluating biodistribution, tumor targeting, and therapeutic effect."
The platform leverages Champions' position as a global preclinical and clinical research services provider offering end-to-end oncology R&D solutions to biopharma organizations. The company maintains the largest and most annotated bank of clinically relevant patient-derived xenograft and primary hematological malignancy models, delivering data through proprietary in vivo and ex vivo platforms.
Strategic Positioning in Growing Market
Champions Oncology's radiopharmaceutical services platform represents a strategic expansion into the rapidly growing targeted radiotherapy market. The company's combination of advanced radiochemistry capabilities with deeply characterized tumor models addresses a critical need in oncology drug development, where traditional preclinical models often fail to predict clinical outcomes.
The successful screening of more than thirty PDX models demonstrates the platform's operational readiness and validates its potential to accelerate radiopharmaceutical development programs. This capability becomes increasingly valuable as pharmaceutical companies seek to develop more precise and effective cancer treatments through targeted radiation delivery.